| P2093 | author name string | Carlos L Arteaga | |
| | Joan T Garrett | |
| P2860 | cites work | HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors | Q24297102 |
| | Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation | Q24306910 |
| | Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3 | Q24309266 |
| | Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab | Q24313194 |
| | Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 | Q24321567 |
| | Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 | Q24633878 |
| | The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 |
| | Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 |
| | Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Q27640593 |
| | A transforming mutation in the pleckstrin homology domain of AKT1 in cancer | Q27646556 |
| | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 |
| | EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 |
| | Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer | Q27851396 |
| | Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 |
| | A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 |
| | NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. | Q27851451 |
| | Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. | Q27851468 |
| | Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer | Q27851549 |
| | Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer | Q27851553 |
| | Untangling the ErbB signalling network | Q27860884 |
| | PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 |
| | PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma | Q28243071 |
| | Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas | Q28287906 |
| | Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions | Q28609149 |
| | Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 |
| | Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 |
| | Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 |
| | Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer | Q33389302 |
| | Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy | Q33393360 |
| | Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells | Q33564297 |
| | An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation | Q33733313 |
| | ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling | Q33886341 |
| | The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity | Q34073138 |
| | Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling | Q34212404 |
| | Differences underlying EGFR and HER2 oncogene addiction | Q34307542 |
| | A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. | Q50767379 |
| | 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 |
| | The PIK3CA gene is mutated with high frequency in human breast cancers. | Q53366750 |
| | Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. | Q53606400 |
| | Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). | Q53985281 |
| | The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. | Q54115075 |
| | Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. | Q54578092 |
| | Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas | Q72016451 |
| | Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer | Q79748462 |
| | Mutation of the PIK3CA gene in ovarian and breast cancer | Q80945762 |
| | Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab | Q81190157 |
| | Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 |
| | A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient | Q34331384 |
| | Lung cancer: intragenic ERBB2 kinase mutations in tumours | Q34354426 |
| | The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis | Q34493341 |
| | Resiliency and vulnerability in the HER2-HER3 tumorigenic driver | Q34551761 |
| | A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer | Q34650878 |
| | Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. | Q34767641 |
| | Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate | Q34880994 |
| | Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. | Q35625995 |
| | Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. | Q35757521 |
| | ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. | Q36490427 |
| | Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases | Q36493822 |
| | Targeting HER proteins in cancer therapy and the role of the non-target HER3. | Q36898642 |
| | Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. | Q36983065 |
| | Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy | Q37163797 |
| | An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer | Q37187915 |
| | Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. | Q37384464 |
| | Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway | Q37515474 |
| | Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer | Q39664583 |
| | H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3 | Q39687743 |
| | Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. | Q39745109 |
| | Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models | Q39771295 |
| | Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. | Q39813764 |
| | An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance | Q39813863 |
| | A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy | Q39960692 |
| | Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells | Q40006240 |
| | Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network | Q40093663 |
| | Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. | Q40144433 |
| | Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells | Q40344963 |
| | Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. | Q40449400 |
| | Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. | Q40461355 |
| | P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. | Q40550119 |
| | Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance | Q40718678 |
| | ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. | Q40966152 |
| | Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action | Q42523855 |
| | Role of exon-16-deleted HER2 in breast carcinomas | Q42803579 |
| | A novel splice variant of HER2 with increased transformation activity | Q42824817 |
| | Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo | Q43829350 |
| | The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. | Q44010450 |
| | Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 |
| | HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. | Q45946352 |
| | Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer | Q46610979 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 793-800 | |
| P577 | publication date | 2011-05-01 | |
| P1433 | published in | Cancer Biology and Therapy | Q2544651 |
| P1476 | title | Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications | |
| P478 | volume | 11 | |